Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Jagannath, Sundar
Lee, Hans C.
Richter, Joshua Ryan
Zonder, Jeffrey A.
Hoffman, James E.
Zhou, Zheng-Yi
Horton, Viviana Garcia
Fillbrunn, Mirko
Wang, Hongjue
Mattera, Matthew
Ma, Qiufei
Inocencio, Timothy J.
Xu, Yingxin
Bergrath, Evelien
Harnett, James
Roccia, Tito
Kroog, Glenn Scott
Rodriguez-Lorenc, Karen
Houvras, Yariv
Bumma, Naresh
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[3] Karmanos Canc Inst, Detroit, MI USA
[4] Univ Miami Hlth Syst, Miami, FL USA
[5] Anal Grp Inc, Boston, MA USA
[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7560
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
    Krishnan, Amrita Y.
    Nooka, Ajay K.
    Chari, Ajai
    Garfall, Alfred L.
    Martin, Thomas G.
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Pei, Lixia
    Eric, Ammann
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok V.
    Slavcev, Mary
    Usmani, Saad Zafar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF TECLISTAMAB VERSUS SELINEXOR-DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM)
    Moreau, P.
    Usmani, S. Z.
    van de Donk, N. W. C. J.
    Garfall, A. L.
    Delforge, M.
    Oriol, A.
    Nooka, A.
    Rosinol, L.
    Bahlis, N.
    Otero, Rodriguez P.
    Martin, T.
    Diels, J.
    Van Sanden, S.
    Pei, L.
    Ammann, E.
    Chastain, K.
    Marshall, A.
    Slavcev, M.
    Londhe, A.
    Krishnan, A.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S31 - S31
  • [3] Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Moreau, Philippe
    Usmani, Saad
    van de Donk, Niels W. C. J.
    Garfall, Alfred
    Delforge, Michel
    Oriol, Albert
    Nooka, Ajay
    Rosinol, Laura
    Bahlis, Nizar
    Rodriguez-Otero, Paula
    Martin, Thomas
    Diels, Joris
    Van Sanden, Suzy
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Marshall, Alexander
    Slavcev, Mary
    Smit, Jennifer
    Londhe, Anil
    Krishnan, Amrita
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S181 - S182
  • [4] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF TECLISTAMAB VS BELANTAMAB MAFODOTIN FOR THE TREATMENT OF PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Moreau, P.
    Usmani, S. Z.
    van de Donk, N. W. C. J.
    Garfall, A. L.
    Delforge, M.
    Oriol, A.
    Nooka, A.
    Rosinol, L.
    Bahlis, N.
    Rodriguez Otero, P.
    Martin, T. G.
    Diels, J.
    Van Sanden, S.
    Pei, L.
    Ammann, E.
    Chastain, K.
    Marshall, A.
    Slavcev, M.
    Londhe, A.
    Krishnan, A.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S5 - S6
  • [5] ADJUSTED COMPARISON OF TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN'S CHOICE (RWPC) OF THERAPY IN PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mateos, M., V
    Chari, A.
    Usmani, S. Z.
    Goldschmidt, H.
    Weisel, K.
    Qi, K.
    Londhe, A.
    Nair, S.
    Lin, X.
    Pei, L.
    Ammann, E.
    Chastain, K.
    Parekh, T.
    Marshall, A.
    Slavcev, M.
    Moreau, P.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S5 - S5
  • [6] Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexordexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).
    Bahlis, Nizar J.
    Usmani, Saad Zafar
    Rosinol, Laura
    Krishnan, Amrita Y.
    Nooka, Ajay K.
    Rocafiguera, Albert Oriol
    Delforge, Michel
    Garfall, Alfred L.
    Van De Donk, Niels W. C. J.
    Iguez-Otero, Paula Rodr .
    Martin, Thomas G.
    Diels, Joris
    Van Sanden, Suzy
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Slavcev, Mary
    Smit, Jennifer
    Londhe, Anil
    Moreau, Philippe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
    Moreau, Philippe
    Usmani, Saad Zafar
    van de Donk, Niels W. C. J.
    Garfall, Alfred L.
    Delforge, Michel
    Rocafiguera, Albert Oriol
    Nooka, Ajay K.
    Rosinol, Laura
    Bahlis, Nizar J.
    Rodriguez-Otero, Paula
    Martin, Thomas G.
    Diels, Joris
    Van Sanden, Suzy
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Slavcev, Mary
    Smit, Jennifer
    Londhe, Anil
    Krishnan, Amrita Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] COMPARATIVE EFFECTIVENESS OF TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN'S CHOICE OF THERAPY (RWPC) FOR PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Krishnan, A.
    Nooka, A.
    Chari, A.
    Garfall, A. L.
    Martin, T.
    Nair, S.
    Lin, X.
    Qi, K.
    Londhe, A.
    Pei, L.
    Ammann, E.
    Chastain, K.
    Parekh, T.
    Marshall, A.
    Slavcev, M.
    Usmani, S. Z.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S37 - S37
  • [9] A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma
    Mol, Isha
    Hu, Yannan
    Leblanc, Thomas W.
    Cappelleri, Joseph C.
    Chu, Haitao
    Nador, Guido
    Aydin, Didem
    Schepart, Alex
    Hlavacek, Patrick
    [J]. LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 660 - 668
  • [10] A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab and Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma
    Mol, Isha
    Hu, Yannan
    LeBlanc, Thomas W.
    Cappelleri, Joseph C.
    Chu, Haitao
    Nador, Guido
    Aydin, Didem
    Schepart, Alex
    Hlavacek, Patrick
    [J]. BLOOD, 2023, 142
12345